My Libido: Where Did It Go?

Sexual Health, Part 2: My Libido — Where Did It Go?

One day you notice it’s just… not there. The spark, the spontaneous wanting, the part of you that used to initiate — faded or gone, and you’re not sure when it happened. If this is you, you’re in enormous company, and you’re not broken. Low desire in midlife is common, it’s real, and — once we understand what’s driving it — it’s often very addressable.

In Part 1 we covered GSM, the physical reason intimacy can start to hurt. But many women tell me the bigger issue isn’t pain — it’s that the desire itself has vanished. So let’s talk honestly about libido: why it changes, the surprisingly long list of things that affect it, and the real options for getting it back.

First: a little perspective on “normal”

There is no universal “right” amount of desire, and libido naturally ebbs and flows across a life. A lower libido is only a problem if it bothers you — if the loss of desire is distressing to you, not merely different from a magazine’s idea of how you should feel. When persistent low desire does cause genuine personal distress, it has a name — hypoactive sexual desire disorder (HSDD) — and it’s remarkably common, affecting a large share of women. Naming it matters, because it’s a real, treatable condition, not a character flaw or an inevitability.

Desire isn’t one switch — it’s a whole circuit board

Here’s the single most important thing to understand: libido is multifactorial. It’s not controlled by one hormone or one cause. It emerges from the interplay of your hormones, your body, your brain, your relationship, your stress, your sleep, and your medications. That’s why “just take testosterone” is rarely the whole answer — and why identifying your specific drivers is what actually works.

Falling estrogen (and the GSM that follows), plus a gradual decline in testosterone, both affect desire and arousal.

If sex hurts, the brain learns to avoid it. Desire can’t flourish when the body braces for discomfort — which is why treating GSM (Part 1) often helps libido too.

You can’t want what you’re too exhausted to contemplate. Poor menopausal sleep is a major, underrated desire-killer.

Anxiety, low mood, and chronic stress (high cortisol) all suppress desire. Midlife tends to pile these on at once.

Antidepressants (especially SSRIs) are common culprits, along with some blood pressure medications and others.

Connection, resentment, boredom, a partner’s own health — the relational context is often the biggest factor of all.

The body changes of midlife can affect how desirable — and how present — a woman feels during intimacy.

Thyroid problems, anemia, chronic illness, alcohol, and general vitality all feed into desire.

A reframe that helps many women: desire often follows, not leads

We tend to assume desire should strike first — a spontaneous bolt that makes us want sex. But for many women, especially in long relationships and midlife, desire is responsive: it shows up after arousal begins, once you’re relaxed, connected, and physically engaged — not before. If you’re waiting to feel spontaneous desire before you’ll be intimate, you may be waiting for the wrong signal. Sometimes willingness and the right conditions come first, and desire follows. This isn’t a flaw; it’s simply how many women’s desire works, and understanding it changes everything.

What actually helps — building your plan

Because libido is multifactorial, the most effective approach addresses your specific contributors rather than reaching for a single magic fix. Here’s the toolkit, roughly in the order I think about it.

Start with the foundation

Fix what’s quietly draining desire

  • Treat GSM (Part 1) — if sex is painful, nothing else will work until that’s addressed. Often this alone brings desire back.
  • Protect sleep — frequently the single highest-yield change.
  • Address mood and stress — and review whether an antidepressant might be dampening desire (there are often workable alternatives or adjustments).
  • Tend the relationship — honest communication, scheduled connection, and sometimes a sex therapist or couples counselor, which is genuinely effective and nothing to be embarrassed about.
  • Move your body, limit alcohol, manage health conditions — vitality and desire travel together.

Hormonal options

Estrogen (systemic or local) — if symptoms like hot flashes, poor sleep, and GSM are in the picture, treating them with hormone therapy often indirectly restores desire by removing what was suppressing it. Local vaginal estrogen in particular, by relieving pain, is frequently a key piece.

Testosterone — yes, women make and need testosterone too, and it declines with age. Here’s the honest, evidence-based picture: for postmenopausal women with HSDD, carefully dosed testosterone — kept within the normal premenopausal female range — can modestly improve sexual desire, arousal, and satisfaction. This is its one evidence-based use. A few important caveats I always share:

  • In the US there’s no FDA-approved testosterone product for women, so it’s prescribed off-label, carefully dosed (often a small fraction of a men’s product), with blood levels monitored to stay in the female range.
  • The good evidence is for postmenopausal women with distressing low desire — not for premenopausal women, and not as a general “energy,” mood, or anti-aging tonic, where evidence is lacking.
  • Long-term safety data beyond about two years are limited, so it’s used thoughtfully and monitored.

FDA-approved medications specifically for low desire

For HSDD, there are now prescription options that act on the brain’s desire circuitry rather than on hormones:

MedicationHow it’s usedNotes
Flibanserin (Addyi)A once-daily oral pillAdjusts brain neurotransmitters involved in desire. As of December 2025, FDA-approved for HSDD in postmenopausal women under 65 (previously premenopausal only) — a notable expansion. No alcohol around dosing.
Bremelanotide (Vyleesi)A self-injection, as-needed before intimacyFDA-approved for premenopausal HSDD. Acts on brain melanocortin pathways. Used on demand rather than daily.
BupropionOral, off-labelSometimes used off-label for low desire, including when an SSRI antidepressant is the culprit. Modest evidence, but a useful tool in the right situation.

The takeaway on treatment

There’s rarely one magic bullet — but there is almost always something that helps, often several things combined. The key is a thoughtful evaluation that sorts out your particular mix: Is it pain? Sleep? A medication? Your relationship? Hormones? The brain’s desire circuitry? Matching the solution to the actual cause is what turns “my libido is gone forever” into a real, workable plan.

The bottom line

  • Low libido in midlife is common and not a character flaw — it’s only a “problem” if it distresses you, and when it does, it has a name (HSDD) and real treatments.
  • Desire is multifactorial — hormones, pain (GSM), sleep, mood, stress, medications, relationship, and health all feed in. There’s rarely one single cause.
  • For many women desire is responsive, not spontaneous — it often follows arousal and connection rather than striking first.
  • Start with the foundation: treat GSM, protect sleep, address mood/medications, and tend the relationship (sex therapy genuinely helps).
  • Hormonal options: estrogen (relieving symptoms that suppress desire) and, for postmenopausal HSDD, carefully dosed testosterone within the female range (off-label in the US, monitored).
  • Brain-targeted medications exist for HSDD — flibanserin (now approved for postmenopausal women under 65), bremelanotide, and off-label bupropion.

Your desire didn’t disappear because something is wrong with you. It faded for understandable, identifiable reasons — and that means it can very often be rekindled.

If your libido has gone quiet and it’s bothering you, please know this is a real medical topic worth a real conversation — not something to be embarrassed about or resigned to. Sorting out your particular picture is exactly the kind of work I love to do.

Coming next in this series

We’ll keep exploring sexual health in midlife and beyond. Stay tuned for the next installment.

Selected References

  1. Evaluation and management of hypoactive sexual desire disorder in women: recommendations from the 5th International Consultation on Sexual Medicine (ICSM 2024). Sex Med Rev. 2025.
  2. Davis SR, et al. Global consensus position statement on the use of testosterone therapy for women (sole evidence-based indication: postmenopausal HSDD; dose to premenopausal female range). J Clin Endocrinol Metab / Climacteric. 2019.
  3. ISSWSH clinical practice guideline on systemic testosterone for HSDD in women.
  4. FDA approval of expanded flibanserin (Addyi) indication for HSDD in postmenopausal women <65 (December 2025).
  5. Bremelanotide (Vyleesi) FDA approval for acquired, generalized HSDD in premenopausal women (2019).
  6. Treatment of HSDD in women: pharmacological options (flibanserin, bremelanotide, bupropion, buspirone) and psychological therapy. Focus (Am Psychiatr Publ). 2020.
  7. Basson R. The female sexual response: responsive desire model. J Sex Marital Ther. 2000.

This article is for educational purposes and reflects the state of the evidence at the time of writing; it is not a substitute for individualized medical advice. Testosterone therapy for women is not FDA-approved in the US and is used off-label; it and all medications discussed carry considerations that should be reviewed with your own clinician. Decisions about hormone therapy, testosterone, and prescription treatments for low desire should be made together with your physician based on your personal health history. Persistent distressing changes in desire can also reflect other medical or psychological conditions worth evaluating.

Scroll to Top